Home/Pipeline/OMBLASTYS® (omburtamab)

OMBLASTYS® (omburtamab)

CNS/Leptomeningeal metastases from neuroblastoma

ApprovedActive

Key Facts

Indication
CNS/Leptomeningeal metastases from neuroblastoma
Phase
Approved
Status
Active
Company

About SERB Pharmaceuticals

SERB Pharmaceuticals is a Belgium-based, global specialty pharma company with a dual focus on emergency medicine (antidotes/CBRN) and rare diseases. Founded in 2008 but tracing its heritage to the 1950s, SERB has built a fully integrated commercial platform, directly selling in 18 countries and supplying over 100. The company is in a clear growth phase, evidenced by strategic acquisitions like Y-mAbs Therapeutics, high-profile leadership appointments, and a pipeline leveraging its antibody platform, positioning it as a critical supplier to healthcare systems and governments worldwide.

View full company profile